Latest Developments
31 August 2010
A5 Laboratories Inc. Completes Validation of CRO Equipment
MONTREAL, QUEBEC–(Marketwire – 08/31/10) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) today announced the CRO team headed by Dr. Matni has completed the validation of the first set of equipment that will be used for the testing of pharmaceutical raw materials and finished products.
24 August 2010
A5 Laboratories Inc. Granted U.S. Provisional Patent Number US 61/400,719 for the Production of Interferon-Based Products
MONTREAL, QUEBEC–(Marketwire – 08/23/10) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) today announced that its previously announced patent application to protect its technology for the production of interferon-based products was accepted by the United States patent office.
Engaged in the Development
and marketing of novel immun theraputic applications of a Natural Gamma-Interferon (nG-IFN)
Our Vision is to Establish a Biotechnology company by developing novel immune therapeutic applications of natural gamma-interferon therapy to treat cancer and infectious diseases.
What is an Interferon?
Interferon (IFN) is a type of protein called a cytokine that is secreted by cells of the body during an infection. It can inhibit viruses from spreading to neighboring cells and it can aid in destroying cancerous cells. Interferon therapy takes advantage of these natural protective properties. Commercial interferon is used as a treatment for viral infections, such as hepatitis C, and as a treatment for certain cancers. Learn more »
What Does A5 Do?
A5 Laboratories provides contract analytical, regulatory and product development services to the Pharmaceutical industry. With a dedicated commitment to its client’s needs, A5 Laboratories offers a full range of services to the pharmaceutical industry in variety of fields, all in compliance with Good Laboratory Practices and current Good Manufacturing Practices regulations.